U.S. regulators approved the drug Pemijatan (pemigatinib) for the treatment of adult patients with advanced cancer of the bile ducts – cholangiocarcinoma.
Cholangiocarcinoma is a rare malignant tumor of epithelial cells of the bile ducts. Pemijatan designed to treat tumors with a mutation in the gene FGFR2.
In support of the registration application of pamyatnaya was sent the results of clinical studies conducted among 107 patients. During testing, the overall response rate was 36%, with 2.8% of patients experienced a complete response, 33% partial response to therapy.